05.05.2026 12:20 Rita Longobardi
Ten Swiss biotech startups have been selected as the 2026 Venture Leaders Biotech team and introduced their innovation during Swiss Biotech Day in Basel. In early June, the group will travel to Boston for a week of investor meetings and business development activities within the US life sciences ecosystem.
Hosted in Basel, Swiss Biotech Day continues to expand its international reach. The 2026 edition brought together a large international audience from across the global biotech sector, including companies, investors, and research institutions. The event has established itself as a key meeting point for senior decision-makers and industry stakeholders from across the life sciences ecosystem.
Switzerland’s biotech industry remains an important part of the national economy and a leading sector for venture capital activity in the country, attracting strong interest from both domestic and international investors.
The day began with an introduction to the roadshow, followed by a workshop on the legal aspects of fundraising, led by program partner VISCHER. In the evening pitch session at Swiss Biotech Day, the selected startups presented their technologies and business cases to an international audience. Patrice Zeis, co-founder and COO of GlioCART, was elected as team captain for the upcoming Boston roadshow.
The 10 startups will follow in the footsteps of high-flying former team members such as Araris Biotech (recently announced its acquisition for USD 1.1 billion), Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105 million funding round in 2023), and BioVersys (recent IPO on the SIX Swiss Exchange).
Follow the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on www.venture-leaders.ch/venture-leaders-biotech from May 31st to June 5th, 2026.
The Venture Leaders Biotech is organized by Venturelab and supported by EPFL, ETH Zurich, University of Basel, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.
Become the next Venture Leader!
